SGEN Seattle Genetics Inc.

120.32
+0.64  (+1%)
Previous Close 119.68
Open 119
Price To Book 11.07
Market Cap 20,767,386,611
Shares 172,601,285
Volume 805,921
Short Ratio
Av. Daily Volume 1,225,342
Stock charts supplied by TradingView

NewsSee all news

  1. Seattle Genetics to Webcast Virtual Fireside Chat at Needham Healthcare Conference

  2. Seattle Genetics Announces Potential Accelerated Approval Pathway in the U.S. for PADCEV™ (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer

    Seattle Genetics, Inc. (NASDAQ:SGEN) today provided an update on the phase 1b/2 multicohort EV-103 trial (also known as KEYNOTE-869) of PADCEVTM (enfortumab vedotin-ejfv) in combination with anti-PD-1 therapy

  3. Seattle Genetics to Webcast Virtual Fireside Chat at Barclays Global Healthcare Conference

    Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay Siegall, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Barclays Global Healthcare Conference on Wednesday, March

  4. Seattle Genetics Announces Cancellation of Presentation and Webcast at the Cowen 40th Annual Healthcare Conference

    Seattle Genetics, Inc. (NASDAQ:SGEN) announced today the cancellation of the Company's presentation and webcast at the Cowen 40th Annual Healthcare Conference on Tuesday, previously scheduled to take place on March 3,

  5. Seattle Genetics to Present at the Cowen 40th Annual Healthcare Conference

    Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Cowen 40th Annual Healthcare Conference on Tuesday, March 3, 2020 at 9:20 a.m. Eastern Time. The presentation will be webcast live

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 trial to be initiated.
SGN-LIV1A (I-SPY 2)
Neoadjuvant for newly diagnosed Stage 2 or 3 HER2 negative breast cancer
Phase 1/2 trial initiated early 2018.
SGN-LIV1A + KEYTRUDA
First-line triple negative breast cancer (TNBC)
Phase 2 data due 1H 2020.
Tisotumab Vedotin (innovaTV 204 )
Cervical Cancer
FDA Approval announced December 18, 2019.
Enfortumab vedotin
Urothelial cancer
Phase 3 trial initiated 2Q 2017.
ADCETRIS and Opdivo
Relapsed Hodgkin Lymphoma
Phase 3 trial initiated mid-2017. Data from Phase 1/2 at ASH 2017 showed a 83% ORR and 62% CR.
ADCETRIS and Opdivo CM-812
Relapsed Hodgkin Lymphoma
Approval announced August 19, 2011.
ADCETRIS
Hodgkin lymphoma and Anaplastic large cell lymphoma
Phase 1/2 clinical hold placed on December 27, 2016 was lifted March 6, 2017. Enrollment halted June 19, 2017 due to safety.
Vadastuximab Talirine (SGN-CD33A)
Myelodysplastic syndrome (MDS)
Phase 1b updated data at SABCS December 7, 2017.
(Tucatinib ONT-380) and T-DM1
HER2+ Metastatic Breast Cancer (MBC)
PDUFA date August 20, 2020 under priority review.
(Tucatinib ONT-380) + Herceptin and Xeloda - HER2CLIMB trial
HER2+ Metastatic Breast Cancer (MBC)
Phase 3 trial discontinued due to higher rate of deaths - June 19, 2017.
Vadastuximab Talirine (CASCADE)
Acute myeloid leukemia (AML) - cancer
sBLA approval announced March 20, 2018. PDUFA date under priority review was May 1, 2018.
ADCETRIS in combination with chemotherapy ECHELON-1
Frontline Hodgkin lymphoma
Phase 2 trial initiated 3Q 2016.
SGN-CD19A
Frontline DLBCL cancer
FDA Approval announced November 16, 2018.
ADCETRIS in combination with chemotherapy - ECHELON-2
Frontline CD30-positive mature T-cell lymphomas - cancer
Approved August 17, 2015 under priority review.
ADCETRIS - AETHERA
Post-transplant Hodgkin lymphoma (HL) cancer
Approval announced November 9, 2017.
ADCETRIS
Cancer - ALCANZA trial for relapsed CD30-positive cutaneous T-cell lymphoma
Phase 3 enrolment completed in January 2020.
Enfortumab vedotin and Keytruda - EV-301
Urothelial cancer
Phase 1b/2 trial has been initiated.
Ladiratuzumab Vedotin
Triple negative breast cancer (TNBC)
Phase 3 trial initiation announced July 9, 2018.
Enfortumab vedotin - EV-301
Urothelial cancer
Phase 2 dosing has commenced - noted July 12, 2018.
Tisotumab Vedotin (innovaTV 207)
Solid tumors
Phase 1/2 updated data presented at ESMO October 20. 2018.
Tisotumab Vedotin (innovaTV 201)
Recurrent Cervical Cancer
PDUFA date under priority review granted January 21, 2020. No PDUFA date supplied. Estimate July 21, 2020 based on 6-month timeline.
GSK’916 - belantamab mafodotin (BCMA)
Multiple myeloma
FDA approval announced June 10, 2019.
Polatuzumab vedotin and bendamustine plus Rituxan (rituximab)
Diffuse large B-cell lymphoma (DLBCL)
Phase 2 presentation at EHA June 15, 2019.
ADCETRIS and Opdivo CM-744
Relapsed/Refractory Classical Hodgkin Lymphoma
Phase 1/2 initial data presented at IASLC 2019 WCLC September 8, 2019.
Enapotamab vedotin
Solid tumors
Phase 2 data at ESMO noted 52% ORR, median PFS 8.1 months, OS of 18.7 months.
Tucatinib - MOUNTAINEER
HER2 amplified metastatic colorectal cancer
Phase 3 trial initiation announced October 10, 2019.
Tucatinib + ado-trastuzumab emtansine (T-DM1, Kadcyla), - HER2CLIMB-02
HER2+ Metastatic Breast Cancer (MBC)
Phase 2 trial initiated January 2020.
Enfortumab vedotin - EV-202
Solid tumors
Phase 1/2 data noted Overall response rate 73%; Complete response rate 16% (partial response rate 58%).
Enfortumab vedotin and Keytruda EV-103
Urothelial cancer

Latest News

  1. Seattle Genetics to Webcast Virtual Fireside Chat at Needham Healthcare Conference

  2. Seattle Genetics Announces Potential Accelerated Approval Pathway in the U.S. for PADCEV™ (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer

    Seattle Genetics, Inc. (NASDAQ:SGEN) today provided an update on the phase 1b/2 multicohort EV-103 trial (also known as KEYNOTE-869) of PADCEVTM (enfortumab vedotin-ejfv) in combination with anti-PD-1 therapy

  3. Seattle Genetics to Webcast Virtual Fireside Chat at Barclays Global Healthcare Conference

    Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay Siegall, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Barclays Global Healthcare Conference on Wednesday, March

  4. Seattle Genetics Announces Cancellation of Presentation and Webcast at the Cowen 40th Annual Healthcare Conference

    Seattle Genetics, Inc. (NASDAQ:SGEN) announced today the cancellation of the Company's presentation and webcast at the Cowen 40th Annual Healthcare Conference on Tuesday, previously scheduled to take place on March 3,

  5. Seattle Genetics to Present at the Cowen 40th Annual Healthcare Conference

    Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Cowen 40th Annual Healthcare Conference on Tuesday, March 3, 2020 at 9:20 a.m. Eastern Time. The presentation will be webcast live

  6. Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for PADCEV™ (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer

    TOKYO and BOTHELL, Wash., Feb. 19, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that the

  7. Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation for PADCEV™ (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer

    - Breakthrough Therapy Designation Based on Initial Results from Phase 1b/2 EV-103 Clinical Trial - Seattle Genetics, Inc. (NASDAQ:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.,

  8. Seattle Genetics Announces FDA Filing Acceptance for Priority Review of Tucatinib New Drug Application (NDA) for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer

    - FDA Action Date is August 20, 2020; Application Under FDA's Real-Time Oncology Review (RTOR) and Orbis Pilot Programs - - Supported by Results from Pivotal HER2CLIMB Trial; First Investigational Therapy in a Pivotal

  9. Seattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV™ (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as Investigational First-Line Treatment for Advanced Bladder Cancer

    - After Median Follow-Up of 11.5 Months, 73 Percent of Patients Had Confirmed Tumor Response with Majority of Responses Still Ongoing; No New Safety Signals Observed for the Combination - - Findings To Be Presented

  10. Seattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV™ (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as Investigational First-Line Treatment for Advanced Bladder Cancer

    BOTHELL, Wash. and TOKYO, Feb. 10, 2020 /PRNewswire/ -- Seattle Genetics, Inc. (NASDAQ:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced updated

  11. Seattle Genetics Reports Fourth Quarter and Full Year 2019 Financial Results

    -ADCETRIS® (Brentuximab Vedotin) Net Sales in U.S. and Canada of $627.7 Million in 2019, Including $166.2 Million in the Fourth Quarter- -PADCEV™ (Enfortumab Vedotin-ejfv) Granted Accelerated Approval by FDA for

  12. EMA Validates Seattle Genetics' Marketing Authorization Application for Tucatinib for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer

    - Application Supported by Results of Pivotal HER2CLIMB Trial - - First Investigational Therapy in a Pivotal Trial to Include Patients with Metastatic HER2-Positive Breast Cancer with Active Brain Metastases - - EU

  13. Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2019 Financial Results on February 6, 2020

    Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it will report its fourth quarter and full year 2019 financial results on Thursday, February 6, 2020 after the close of financial markets. Following the

  14. Seattle Genetics Achieves Milestone Following European Commission Approval of Roche's Polivy® (Polatuzumab Vedotin)

    Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that it will receive a milestone payment from Roche triggered by European Commission conditional marketing authorisation for Polivy® (polatuzumab vedotin). Polivy is

  15. Seattle Genetics to Present at the J.P. Morgan Healthcare Conference

    Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 2:30 p.m. Pacific Time. Both the presentation and

  16. Seattle Genetics Announces Submission of Tucatinib New Drug Application to the U.S. FDA for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer

    – Submission Based on Positive Pivotal HER2CLIMB Trial Results Recently Presented at the 2019 San Antonio Breast Cancer Symposium and Published in the New England Journal of Medicine – – FDA Granted Breakthrough

  17. FDA Grants Accelerated Approval to Astellas' and Seattle Genetics' PADCEV™ (enfortumab vedotin-ejfv) for People with Locally Advanced or Metastatic Urothelial Cancer, the Most Common Type of Bladder Cancer

    TOKYO and BOTHELL, Wash., Dec. 18, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that the

  18. Seattle Genetics to Host Conference Call and Webcast on December 19, 2019 to Discuss PADCEVTM (enfortumab vedotin-ejfv) Approval

    Seattle Genetics, Inc. (NASDAQ:SGEN) will host a conference call and webcast on Thursday, December 19, 2019 to discuss the U.S. Food and Drug Administration approval of PADCEVTM (enfortumab vedotin-ejfv). Access to the

  19. FDA Grants Accelerated Approval to Astellas' and Seattle Genetics' PADCEV™ (enfortumab vedotin-ejfv) for People with Locally Advanced or Metastatic Urothelial Cancer, the Most Common Type of Bladder Cancer

      - First-in-Class Antibody-Drug Conjugate Directed Against Nectin-4, a Protein Highly Expressed in Urothelial Tumors1,2 - - PADCEV is the First Treatment Approved for Locally Advanced or Metastatic Urothelial Cancer

  20. Seattle Genetics Announces U.S. FDA Grants Breakthrough Therapy Designation for Tucatinib in Locally Advanced or Metastatic HER2-Positive Breast Cancer

    - Designation Based on Positive Pivotal HER2CLIMB Trial Evaluating Tucatinib in Locally Advanced or Metastatic HER2-Positive Breast Cancer; Data were Presented at 2019 SABCS and Published in the New England Journal of

  21. Annual Changes to the NASDAQ-100 Index

    NEW YORK, Dec. 13, 2019 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual evaluation of the NASDAQ-100 Index® (NASDAQ:NDX), which will become effective prior to market open on Monday,

  22. Seattle Genetics Announces Positive Tucatinib HER2CLIMB Trial Results in Locally Advanced or Metastatic HER2-Positive Breast Cancer Presented at 2019 SABCS and Published in the New England Journal of Medicine

    - First HER2 Tyrosine Kinase Inhibitor in Combination to Show Improved Progression-Free Survival and Overall Survival in Patients with Metastatic HER2-Positive Breast Cancer With or Without Brain Metastases - - NDA

  23. Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS® (Brentuximab Vedotin) ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at the 2019 ASH Annual Meeting

    - Four-Year Data Continue to Show Superior Progression-Free Survival of ADCETRIS in Combination with AVD when Compared to ABVD in Frontline Advanced Hodgkin Lymphoma with 31 Percent Reduction in the Risk of Progression

  24. Seattle Genetics Announces Updated Data of ADCETRIS® (Brentuximab Vedotin) in Combination with OPDIVO® (Nivolumab) in Frontline and Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting

    - Additional Analysis in Phase 2 Trial of ADCETRIS plus OPDIVO in Patients with Frontline Hodgkin Lymphoma Aged 60 Years and Older - - Two-Year Follow-up Results from Phase 1/2 Trial in Relapsed Hodgkin Lymphoma -

  25. Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer

    BOTHELL, Wash., and TOKYO, Dec. 2, 2019 /PRNewswire/ -- Seattle Genetics, Inc. (NASDAQ:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas"), today announced a clinical

  26. Seattle Genetics Announces Health Canada Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy in Frontline CD30-Expressing Peripheral T-Cell Lymphoma

    - Approval of Supplemental New Drug Submission for ADCETRIS in Combination with CHP Chemotherapy in Frontline CD30-Expressing Peripheral T-Cell Lymphoma based on Positive Phase 3 ECHELON-2 Clinical Trial Results

  27. Seattle Genetics Submits Arbitration Demand Against Daiichi Sankyo Over Technology Ownership

    Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that it has submitted an arbitration demand to the American Arbitration Association to resolve its dispute with Daiichi Sankyo Co. Ltd. regarding the ownership of

  28. Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentations at the ASH Annual Meeting

    -Four-Year Update of the ECHELON-1 Trial Continues to Support Superior Clinical Activity of ADCETRIS in Combination with Chemotherapy when Compared to ABVD in Frontline Advanced Hodgkin Lymphoma- -Additional Data

  29. Seattle Genetics and BeiGene Announce Global License Agreement for Advanced Preclinical Product Candidate

    -BeiGene and Seattle Genetics to Collaborate on Global Clinical Trials- Seattle Genetics, Inc. (NASDAQ:SGEN) and BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)) today announced that the companies have entered into a license

  30. Seattle Genetics Responds to Daiichi Sankyo's Complaint for Declaratory Judgment

    Seattle Genetics, Inc. (NASDAQ:SGEN) today released the following statement in response to Daiichi Sankyo's filing of a Declaratory Judgment action alleging Seattle Genetics is not entitled to intellectual property

  31. Seattle Genetics to Present at Credit Suisse 28th Annual Healthcare Conference

    Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Credit Suisse 28th Annual Healthcare Conference on Tuesday, November 12, 2019 at 10:20 a.m. Mountain Time. The presentation will

  32. Seattle Genetics Reports Third Quarter 2019 Financial Results

    -Record ADCETRIS® (Brentuximab Vedotin) Net Sales in U.S. and Canada of $167.6 Million in the Third Quarter, an Increase of 32 Percent Over the Third Quarter of 2018- -Enfortumab Vedotin Biologics License Application

  33. Seattle Genetics Announces Positive Topline Results from Pivotal Trial of Tucatinib in Locally Advanced or Metastatic HER2-Positive Breast Cancer

    -HER2CLIMB Trial Met Primary Endpoint and Both Key Secondary Endpoints- -Global Regulatory Strategy Includes NDA Submission to U.S. FDA Planned for First Quarter of 2020- -Data to be Presented at the 2019 San

  34. Seattle Genetics Announces Initiation of Phase 3 Clinical Trial of Tucatinib in Combination with Ado-trastuzumab Emtansine (T-DM1, Kadcyla®) for Patients with Advanced or Metastatic HER2-Positive Breast Cancer

    Seattle Genetics, Inc. (NASDAQ:SGEN) today announced dosing of the first patient in HER2CLIMB-02, a randomized phase 3 clinical trial evaluating investigational agent tucatinib versus placebo, in combination with

  35. Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2019 Financial Results on October 29, 2019

    Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it will report its third quarter 2019 financial results on Tuesday, October 29, 2019 after the close of financial markets. Following the announcement, company

  36. Initial Results from MOUNTAINEER Trial Show Antitumor Activity of Tucatinib Combination in HER2-Positive Metastatic Colorectal Cancer

    - First Presentation of Tucatinib With Trastuzumab in Metastatic Colorectal Cancer - - Findings Presented Today at the European Society for Medical Oncology (ESMO) 2019 Congress - Seattle Genetics, Inc. (NASDAQ:SGEN)

  37. Seattle Genetics and Astellas Announce Results from Phase 1 Trial of Investigational Agent Enfortumab Vedotin in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Bladder Cancer

    BOTHELL, Wash. and TOKYO, Sept. 28, 2019 /PRNewswire/ -- Seattle Genetics, Inc. (NASDAQ:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced initial

  38. Seattle Genetics Announces Presentations of New Clinical Data from Multiple Studies of Novel Targeted Therapies at the European Society for Medical Oncology (ESMO) 2019 Congress

    – First Presentation of Initial Data from a Phase 1 Trial of Enfortumab Vedotin Plus Pembrolizumab in Locally Advanced or Metastatic Urothelial Cancer Featured in an Oral Session – Seattle Genetics, Inc. (NASDAQ:SGEN)

  39. Seattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer

    BOTHELL, Wash. and TOKYO, Sept. 16, 2019 /PRNewswire/ -- Seattle Genetics, Inc. (NASDAQ:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that the

  40. Seattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer

    - Food & Drug Administration Sets Prescription Drug User Fee Action Date for March 15, 2020 - Seattle Genetics, Inc. (NASDAQ:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.,